Featured Posts

Tuesday, January 15, 2019

2-Methoxyestradiol attenuates testosterone-induced benign prostate hyperplasia.

PMID:  Oxid Med Cell Longev. 2018 ;2018:4389484. Epub 2018 Aug 1. PMID: 30154949 Abstract Title:  2-Methoxyestradiol Attenuates Testosterone-Induced Benign Prostate Hyperplasia in Rats through Inhibition of HIF-1/TGF-/Smad2 Axis. Abstract:  Benign prostatic hyperplasia (BPH) is a common disorder in the male population. 2-Methoxyestradiol (2ME) is an end metabolite of estrogens with pleiotropic pharmacological properties. This study aimed to explore the potential ameliorative effects of 2ME against testosterone-induced BPH in rats. 2-Methoxyestradiol (50 and 100 mg/kg, dissolved in DMSO) prevented the rise in prostatic index and weight in comparison to testosterone-alone-treated animals for 2 weeks. Histological examination indicated that 2ME ameliorated pathological changes in prostate architecture. This was confirmed by the ability of 2ME to decrease the glandular epithelial height when compared to the testosterone group. Also, 2ME improved testosterone-induced oxidative stress as it inhibited the rise in lipid peroxide content and the exhaustion of superoxide dismutase (SOD) activity. The beneficial effects of 2ME against the development of BPHwere substantiated by assessing proliferation markers, preventing the rise in cyclin D1 protein expression and enhancing Bax/Bcl2 mRNA ratio. It significantly reduced prostate content of tumor necrosis factor(TNF-), interleukin-1(IL-1), nuclear factorB (NF-B), and transforming growth factor(TGF-). In addition, 2ME reduced hypoxia-inducible factor 1-(HIF-1) and phospho-Smad2 (p-Smad2) protein expression compared to the testosterone group. In conclusion, 2ME attenuates experimentally induced BPH by testosterone in rats through, at least partly, inhibition of HIF-1/TGF-/Smad2 axis.

read more



from GreenMedInfo http://bit.ly/2sqCtwP

No comments:

Post a Comment